Search hospitals > California > San Diego

UCSD Medical Center

Claim this profile
San Diego, California 92103
Global Leader in Cancer
Global Leader in Pancreatic Cancer
Conducts research for Lung Cancer
Conducts research for Breast Cancer
Conducts research for Stroke
183 reported clinical trials
29 medical researchers
Photo of UCSD Medical Center in San DiegoPhoto of UCSD Medical Center in San DiegoPhoto of UCSD Medical Center in San Diego

Summary

UCSD Medical Center is a medical facility located in San Diego, California. This center is recognized for care of Cancer, Pancreatic Cancer, Lung Cancer, Breast Cancer, Stroke and other specialties. UCSD Medical Center is involved with conducting 183 clinical trials across 569 conditions. There are 29 research doctors associated with this hospital, such as Lyudmila A. Bazhenova, Sandip Patel, MD, Shumei Kato, and Rana McKay, MD.

Area of expertise

1Cancer
Global Leader
UCSD Medical Center has run 24 trials for Cancer. Some of their research focus areas include:
Stage IV
KRAS positive
BRAF positive
2Pancreatic Cancer
Global Leader
UCSD Medical Center has run 23 trials for Pancreatic Cancer. Some of their research focus areas include:
Stage IV
Stage III
PD-L1 positive

Top PIs

Clinical Trials running at UCSD Medical Center

Cancer
Skin Cancer
Pancreatic Cancer
Lung Cancer
Stroke
Kidney Cancer
Breast Cancer
Breast cancer
Ovarian Cancer
Alzheimer's Disease
Image of trial facility.

Radiation Therapy

for Brain Metastasis

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.
Recruiting2 awards Phase 312 criteria
Image of trial facility.

Triptorelin

for Cancer

This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part of standard chemotherapy, but may cause damage to the ovaries. If the ovaries are not working well or completely shut down, then it will be difficult or impossible to get pregnant in the future. Triptorelin works by blocking certain hormones and causing the ovaries to slow down or pause normal activity. The triptorelin used in this study stays active in the body for 24 weeks or about 6 months after a dose is given. After triptorelin is cleared from the body, the ovaries resume normal activities. Adding triptorelin before the start of chemotherapy treatment may reduce the chances of damage to the ovaries.
Recruiting2 awards Phase 34 criteria
Image of trial facility.

Radiation Therapy

for Cancer with Bone Metastasis

This phase III trial compares the effect of adding radiation therapy to usual care on the occurrence of bone-related complications in cancer patients with high-risk bone metastases that are not causing symptoms (asymptomatic). High-risk bone metastases are defined by their location (including hip, shoulder, long bones, and certain levels of the spine), or size (2 cm or larger). These bone metastases appear to be at higher risk of complications such as fracture, spinal cord compression, and/or pain warranting surgery or radiation treatment. Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. The total dose of radiation can be delivered in a single day or divided in smaller doses for up to 5 days of total treatment. Usual care for asymptomatic bone metastases may include drugs that prevent bone loss, in addition to the treatment for the primary cancer or observation (which means no treatment until symptoms appear). Evidence has shown that preventative radiation therapy may be effective in lowering the number of bone metastases-related complications, however, it is not known if this approach is superior to usual care. Adding radiation therapy to usual care may be more effective in preventing bone-related complications than usual care alone in cancer patients with asymptomatic high-risk bone metastases.
Recruiting2 awards Phase 37 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at UCSD Medical Center?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security